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Original article
Hypoallergenic fragment of Par j 2 increases functional expression
of Toll-like receptors in atopic children
Parietaria judaica, a grassy plant belonging to the family
Urticaceae, is one of the main causes of allergy in the
Mediterranean area (1). Parietaria ﬂowers from spring to
autumn and this long pollen season may account for the
prevalence of this pollinosis in this area (2). This pollen
contains at least nine allergens, and two of them, named
Par j 1 and Par j 2, have been cloned and sequenced (3, 4).
The allergeneity of this pollen is crucially dependent by a
three-dimensional structure generated by the presence of
four disulphide bridges as result of the pairing of the eight
cysteine residues (5). The modiﬁcation of allergen B-cell
epitopes represents an approach to obtain hypoallergens
that would increase the safety of allergen-speciﬁc immu-
notherapy (SIT; 6).
Several epidemiologic studies shed light on the possible
protective inﬂuences of natural microbial exposure on
atopy and asthma development and has led to the
formulation of the hygiene hypothesis (7, 8). The lack
of Th1-inducing factors, i.e. the reduction of pathogen-
associated molecular patterns (PAMP), which are detec-
ted by accessory cells expressing Toll-like receptors
(TLR), is associated with the germ-reduced living stand-
ard in the cities of the so-called western world (7). This
coincides with an increase of Th2-mediated disorders,
such as allergic bronchial asthma and atopic dermatitis in
the urban population, which are not detected in the rural
population (9). Toll-like receptor stimulation on profes-
sional antigen-presenting cells (APC) increases the pro-
duction of interleukins (IL) 12 and 23 and promotes the
expansion of APC with enhanced and sustained T helper
type 1-polarizing capacity (10). The associated increase in
interferon (IFN)c may steer our immune system away
from the allergy-driven type-2 helper T-cell phenotype.
According to this hypothesis, a constant Th1 triggering
balances the immune system, and the removal of these
triggers skews the system toward Th2. As regards, it has
been demonstrated that a combination of TLR and
IFN-c receptor stimulation of dendritic cells (DC) results
in a shift from a Th2- to a Th1-like response in a
coculture system with appropriately pretreated DC and
autologous lymphocytes from allergic subjects (11). The
present study was performed using both an in vitro and an
in vivo approaches and was aimed to evaluate whether the
alteration in the molecular structure of Par j 2 may aﬀect:
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(i) the allergenic activity of Par j 2; (ii) the proinﬂamma-
tory activity of Par j 2; (iii) the expression and the
activation of TLRs; and (iv) the release of IFNc.
Materials and methods
Subjects
We selected 10 allergic patients with mild intermittent asthma (age
7–16 years), according to the criteria of the American Thoracic
Society. The diagnosis of asthma and the assessment of its severity
were performed at study entry according to Global Initiative for
Asthma (12). All subjects were monosensitized to P. judaica pollen
as assessed by skin prick tests including a panel of allergens
(Stallergene`s) and by evaluation of total and speciﬁc immunoglob-
ulin (Ig)E concentrations (CAP System Pharmacia-Upjohn,
Uppsala, Sweden). None of the patients received any corticosteroid
or antihistamine treatment during the previous 2 weeks. The study
fulﬁlled the criteria of the Ethics Committee of our Hospital and all
subjects and/or their parents had given their informed consent.
Demographic characteristics of recruited patients are reported in
Table 1.
Generation of recombinant Par j 2 and of molecular variants
The cDNA cloning, expression and preparation of Escherichia coli
cell lysates, puriﬁcation and sequence analysis of rPar j 2 were
performed as previously described (3). The two fragments (patent
No. CNR RM 99 A 000737) were generated as previously described
(13) including some modiﬁcations. In particular, we constructed a
fragment containing the ﬁrst 55 amino acids of Par j 2 (1–55) and a
fragment containing the amino acids 52–102. To eliminate disulﬁde
bridges and to disrupt the three-dimensional structure in the 1–55
fragment, as the disulphide bridges are generated between cysteine
residues, using a polymerase chain reaction mutagenesis method,
four cysteine residues were substituted by alanine residues (Fig. 1).
The amino acid exchange was performed at the positions 4, 14, 49
and 52. The sequence of the used oligonucleotides for 1–55 fragment
are: 5¢: Bam Q gtg-GGA-TCC-gag-gag-gct-gcc-ggg-aaa-gtg-gtg-
cag-gat-ata-atg-ccg-gcc-ctg; 1–55 3¢: HindIII cac-AAG-CTT-gcg-
cac-tat-gca-ctt-gca-ggc-ctc-cct-ctt. Bold and capital letters indicate
the mutated nucleotides and sites of restriction enzymes, respect-
ively. All the generated molecules were expressed in a vector (pQE
30) containing a six histidine tag for their aﬃnity puriﬁcation, did
not contain detectable amounts of lipopolysaccharide (LPS) and
were >99% pure. The presence of contaminating LPS was assessed
by a commercially available kit (Cambrex Corporation, East Ru-
therfort, NJ) and was below the detection limit of 0.1 EU/ml.
Skin prick test
Skin prick test on children was performed with rPar j 2 and 1–55
and 52–102 fragments. About 20 ll of rPar j 2 (20 lg/ml) and of
molecular variants (10 lg/ml), diluted in sterile water, were applied
on forearms of patients and pricked with sterile lancets. The con-
centration range (from 1 to 20 lg/ml) was previously shown to be
optimal in preliminary experiments (data not shown). Reactions
were recorded after 20 min by transferring the ballpoint pen-sur-
rounded wheal area with a transparent tape to paper. We measured
the maximal longitudinal and transversal diameters of the wheal
area.
Peripheral blood mononuclear cells cultures
Peripheral blood mononuclear cell (PBMC), obtained from 20 ml of
heparinized blood from atopic children, were separated by Ficol–
Hypaque-gradient centrifugation. Peripheral blood mononuclear
cell were incubated in the presence and in the absence of rPar j 2
(20 lg/ml), of 1–55 and of 52–102 fragments (10 lg/ml). The con-
centration range (from 1 to 40 lg/ml) and incubation times (4, 8
and 18 h) were previously shown to be optimal in preliminary
experiments (data not shown). Peripheral blood mononuclear cell
were cultured (37C, 5% CO2) with the stimuli for 18 h and
expression of CD45R0, chemotactic activity, expression of TLR2
and TLR4, LPS binding and IFNc release were then assessed.
Chemotaxis assay
Neutrophils were puriﬁed from atopic children and chemotaxis
toward neutrophils was performed as previously described (14),
using a microchemotaxis chamber (Costar, Neuro Probe Inc., Cabin
John, MD, USA).
Expression of CD45R0
The expression of CD45RO was assessed by ﬂow cytometry by a
FITC-conjugated speciﬁc mouse monoclonal antibody (Pharmin-
gen, San Diego, CA, USA) using a FACStar Plus (Becton Dickin-
son, Mountain View, CA, USA) analyzer. Negative controls were
Table 1. Demographic characteristics of patients
Subject
number
Age
(years) Sex
IgE
(IU/ml)
Eos/
mm3
RAST Par J
(KU/l)
FEV1
(% prediction)
r-Par j 2
(mm)
1 14 M 1003 600 >100 81 4 · 4
2 16 M 1250 930 >100 93 8 · 5
3 7 F 1571 800 70.65 84 2 · 5
4 16 F 819 811 12.02 107 3 · 4
5 12 M 491 560 >100 100 2 · 4
6 8 F 290 1370 97.76 118 6 · 4
7 13 M 1273 1140 89.40 93 14 · 13
8 11 F 248 300 >100 80 3 · 3
9 12 F 698 690 >100 101 2 · 2
10 7 F 533 790 >100 100 2 · 5
Eos, eosinophils.
XCXXXXCXXXXXXCCXXXXXXXCXCXXXXXXXXXXXCXXXXXXCX
4 14 29 30 50 52 75 90
C4 C14 C29 C501 C30 C52 55
A4 A14 C29 A501 C30 A52 55
52 102C75 C90
Disulphide link
Native Par j 
Par j 2 
Figure 1. Schematic representation of rPar j 2, of 1–55 and 52–
102 fragments.
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performed using a mouse FITC-conjugated IgG1 (Dako, Glostrup,
Denmark). Data are expressed as percentage of positive cells.
Expression of TLR2 and of TLR4 by PBMC
The expression of TLR2 and of TLR4 was evaluated by ﬂow cy-
tometry using speciﬁc rabbit monoclonal antibodies anti-TLR2 and
anti-TLR4 (Santa Cruz Biotechnology, Santa Cruz, CA) followed
by a FITC-conjugated antirabbit IgG (Dako). Negative controls
were performed using rabbit immunoglobulin-negative control
(Dako). Data are expressed as geomean ﬂuorescence intensity. The
positivity of the cells was evaluated on the gate of monocytes.
The speciﬁcity for monocytes of the designed gate, was also
conﬁrmed by the high percentage of CD14-positive (Dako) cells
present within this gate, as assessed by preliminary experiments
(data not shown).
Binding of LPS
The binding of LPS was assessed using ALEXA ﬂuor LPS
(Molecular Probe, Invitrogen, Carlsband, CA). In particular,
PBMC stimulated as described above, were incubated with ALEXA
ﬂuor LPS for 30¢ and the binding of LPS was evaluated by ﬂow
cytometry.
Measurement of IFNc
The concentration of IFNc was determined with an enzyme-linked
immunosorbent assay (ELISA; Quantikine; R&D Systems, Min-
neapolis, MN) following the manufacturer’s direction.
Statistics
Data are expressed as mean ± SD. Statistical analysis was per-
formed using anova with the Bonferroni test. P < 0.05 was ac-
cepted as statistically signiﬁcant.
Results
In vivo effects of rPar j 2 and of 1–55 and 52–102 fragments
We ﬁrst evaluated whether the structural diﬀerences of
1–55 and 52–102 fragments in comparison with rPar j 2,
may account for a diﬀerent allergenicity in skin prick test
experiments. The results of the skin prick tests are shown
in Table 1. All patients showed pronounced immediate
type skin reactions to rPar j 2. The two fragments did not
promote any skin reaction (data not shown). All patients
displayed immediate and positive reaction to histamine
(data not shown).
Effects of rPar j 2 and of 1–55 and 52–102 fragments on neutrophil
chemotaxis
Having established that the two fragments of Par j 2 were
hypoallergenic, we assessed, using an in vitro model,
whether PBMC stimulated with rPar j 2 and with both
fragments generated a diﬀerent chemotactic activity
toward neutrophils. Interestingly, following stimulation
with rPar j 2, PBMC exerted chemotactic activity toward
neutrophils. In contrast, PBMC, upon stimulation with
the two fragments, were not able to exert this chemotactic
activity (Fig. 2).
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Figure 2. Chemotactic activity toward neutrophils of rPar j 2,
1–55 and 52–102 fragments. Peripheral blood mononuclear cell
(PBMC) and peripheral blood neutrophils were isolated from
asthmatic and atopic children. PBMC were cultured in the ab-
sence or in the presence of rPar j 2, 1–55 and 52–102 fragments
for 18 h (see Materials and methods for details). Cell superna-
tants were collected and were used to stimulate chemotaxis to-
ward neutrophils (n ¼ 10) using a microchemotaxis chamber
(see Materials and methods for details). Data are expressed as
number of transmigrated cells. *P < 0.001 compared with the
baseline.
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Figure 3. Eﬀect of rPar j 2, 1–55 and 52–102 fragments on the
expression of CD45RO by peripheral blood mononuclear cell
(PBMC). PBMC isolated from asthmatic and atopic children
and cultured in the absence or in the presence of rPar j 2, 1–55
and 52–102 fragments for 18 h, were assessed for CD45RO
expression by ﬂow cytometry (see Materials and methods for
details). Data are expressed as percentage of positive cells.
*P < 0.004 compared with the baseline.
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Effects of rPar j 2 and of 1–55 and 52–102 fragments on CD45RO
expression by PBMC
As in subjects with atopic asthma, following allergen
challenge, there is an increase in CD45RO-positive
memory T lymphocytes (15), which are responsible of
the release of higher concentrations of Th2 cytokines
typically present in allergic subjects (16), we evaluated the
eﬀects of rPar j 2 and of 1–55 and 52–102 fragments on the
expression of CD45RO molecule by PBMC from allergic
asthmatic children. Interestingly, while rPar j 2 was able
to signiﬁcantly increase the number of CD45RO-positive
cells, both 1–55 and 52–102 fragments did not, conﬁrming
that the two fragments of Par j 2 are diﬀerently recognized
by immune system of the studied patients (Fig. 3).
Effects of rPar j 2 and of 1–55 and 52–102 fragments on TLR2 and
TLR4 expression by PBMC
We then evaluated whether the recombinant native
allergen and the two fragments diﬀerently aﬀected the
expression of TLR2 and TLR4. While the recombinant
allergen and the 52–102 fragment were not able to
signiﬁcantly increase the expression of TLR2 (Fig. 4) and
of TLR4 (Fig. 5), the 1–55 fragment signiﬁcantly
increased the expression of both receptors.
Effects of rPar j 2 and of 1–55 and 52–102 fragments on LPS
binding
As the activation of TLR4 receptor preferentially induces
Th1 responses, we established whether the expression of
TLR4 was functionally active by evaluating the binding
of LPS. Interestingly, while rPar j 2 and 52–102 fragment
were not able to signiﬁcantly increase the binding of LPS,
1–55 fragment signiﬁcantly increased LPS binding
(Fig. 6).
Effects of rPar j 2 and of 1–55 and 52–102 fragments on IFNc
release
Finally, we assessed whether the upregulation of func-
tionally active TLR4 receptors was associated with an
increased release of IFNc. Interestingly, the stimulation
of PBMC with 1–55 fragment leaded to an increased
release of IFNc. In contrast, rPar j 2 and 52–102
fragment were not able to increase the release of IFNc
(Fig. 7).
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Figure 4. Eﬀect of Par j 2rPar j 2, 1–55 and 52–102 fragments on the expression of Toll-like receptor (TLR)2 by peripheral blood
mononuclear cell (PBMC). (A) PBMC isolated from asthmatic and atopic children and cultured in the absence or in the presence of
rPar j 2, 1–55 and 52–102 fragments for 18 h, were assessed for TLR2 expression by ﬂow cytometry. Data are expressed as geomean
ﬂuorescence intensity. *P < 0.001 compared with the baseline. (B) Histograms from a representative experiment.
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Discussion
Parietaria judaica certainly represents one of the main
causes of allergy in the Mediterranean countries. One of
the most important allergens of P. judaica is represented
by Par j 2, as it has been previously demonstrated that
83% of the sera from the Mediterranean atopic patients
showed IgE reactivity to this allergen (2). Here, we
demonstrate for the ﬁrst time that a hypoallergenic
fragment of Par j 2, the 1–55 fragment, missing the
anaphylactic and proinﬂammatory properties of recom-
binant allergen with native conformation, is able to
increase the expression of innate immunity receptors
TLR2 and TLR4, the LPS binding and the release of
IFNc by PBMC. These ﬁndings support the recent
proposed use of modiﬁed allergens in the SIT of allergic
patients (17) and unveil for the ﬁrst time some molecular
mechanisms potentially responsible of the success of this
new approach.
Allergen-speciﬁc immunotherapy is an eﬀective treat-
ment for type I allergy modifying the natural course of
the disease by preventing the evolution from rhinitis to
asthma and the onset of sensitization against new
allergens (18). The main problem of conventional SIT is
the risk of possible anaphylactic reactions. The three-
dimensional structure of an antigen and its recognition
by diﬀerent APC seem to be crucial aspects in the
production of Th2 cytokines as well as of IgE
antibodies (19). One strategy for the development of
molecular variants of Par j with reduced allergenic
activities is based on the disruption of the allergen’s
three-dimensional structure by site-directed mutagenesis
targeted to disrupt disulﬁde bridges (5) and by
synthesizing peptides comprising the N-terminal or the
C-terminal half of the allergen.
On the basis of these concepts, we disrupted the
three-dimensional structure of Par j 2 major allergen by
fragmentation and by site-directed mutagenesis. We
ﬁrst assessed whether the generated fragments were, in
comparison with recombinant Par j 2 native allergen,
hypoallergenic in vivo, by skin prick test. rPar j 2 has
been shown to possess immunologic properties equiv-
alent to its natural counterpart and its availability
represents a fundamental tool for the diagnosis and
therapy of Parietaria pollen allergy (2). It is well
established that, due to the presence of some cross-
reactivity with other allergens, the use of rPar j 2 may
be useful to unambiguously identify the disease-eliciting
allergen sources (2). We conﬁrmed, using rPar j 2,
that all the studied patients were genuinely allergic to
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Figure 5. Eﬀect of rPar j 2, 1–55 and 52–102 fragments on the expression of Toll-like receptor (TLR)4 by peripheral blood mono-
nuclear cell (PBMC). (A) PBMC isolated from asthmatic and atopic children and cultured in the absence or in the presence of rPar j 2,
1–55 and 52–102 fragments for 18 h, were assessed for TLR4 expression by ﬂow cytometry. Data are expressed as geomean ﬂuor-
escence intensity. *P < 0.001 compared with the baseline. (B) Histograms from a representative experiment.
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P. judaica pollen. Furthermore, we demonstrated that
both 1–55 and 52–102 fragments lost their anaphylactic
activity as none of the Parietaria monosensitized
children showed any positive skin reaction to allergen
fragments.
To further characterize the functional diﬀerences
between rPar j 2 and the two fragments, we evaluated
whether all these molecules diﬀerently aﬀected the
expression of CD45RO+ T cells and the chemotactic
activity toward neutrophils by PBMC. We demonstrated
that the generated fragments lost the ability to induce a
chemotactic activity toward neutrophils as the native
counterpart. Furthermore, both fragments (1–55 and 52–
102) were diﬀerently recognized by immune cells as they
did not increase the number of CD45RO+ memory T
cells as the rPar j 2 did.
The hygiene hypothesis is considered the most reason-
able explanation for the allergy epidemics in western
countries that has occurred over the past few decades
(8, 9). The immunologic mechanisms on the basis of the
hygiene hypothesis are a missing immune deviation of
allergen-speciﬁc responses from a Th2 to a type Th1
proﬁle and a reduced activity of T-regulatory cells (20).
As regards, it has been demonstrated that TLR-4
signaling may promote the induction of IL-10-secreting
type 1 regulatory T cells (21). We evaluated the IL-10
production by stimulated PBMC in order to explore the
eﬀects of the rPar j 2 and of the fragments on the activity
of T-regulatory cells. We did not observe any signiﬁcantly
increased release of IL-10 following molecular variants
exposure (data not shown). This phenomenon was
probably due to the fact that our model of in vitro
stimulation includes a single antigen exposure while the
regulatory cell number appears to arise following repea-
ted antigen stimulation, either in vitro or in vivo (22).
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Figure 6. Eﬀect of Par j 2rPar j 2, 1–55 and 52–102 fragments on the binding of lipopolysaccharide (LPS) by peripheral blood
mononuclear cell (PBMC). (A) PBMC isolated from asthmatic and atopic children and cultured in the absence or in the presence of
rPar j 2, 1–55 and 52–102 fragments for 18 h, were assessed for LPS binding by ﬂow cytometry. Data are expressed as geomean
ﬂuorescence intensity. *P < 0.03 compared with the baseline. (B) Histograms from a representative experiment.
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Figure 7. Eﬀect of Par j 2rPar j 2, 1–55 and 52–102 fragments
on the release of interferon (IFN)-c by peripheral blood
mononuclear cell (PBMC). PBMC were cultured in the absence
or in the presence of rPar j 2, 1–55 and 52–102 fragments for
18 h (see Materials and methods for details). Cell supernatants
were collected and IFNc release was assessed by enzyme-linked
immunosorbent assay. Data are expressed as pg/ml of IFNc and
represent mean ± SD of 10 experiments (*P < 0.002).
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A reduced activation (11) or expression (23) of speciﬁc
TLRs may account for a missing immune deviation of
allergen-speciﬁc responses from a Th2 to a Th1 proﬁle.
On the basis of these concepts, we evaluated whether the
recombinant allergen with native conformation and the
two fragments diﬀerently aﬀected the expression of TLR2
and TLR4 innate immune receptors. We demonstrated
that the 1–55 fragment signiﬁcantly increased the expres-
sion of both TLR2 and TLR4 in PBMC from recruited
allergic children. In contrast, the native allergen and the
52–102 fragment did not. Consequently, the 1–55 frag-
ment via the upregulation of innate immune receptors
may have the potential to ameliorate the Th2 immune
deviation of allergic subjects. To assess whether the
expression of these receptors, and in particular of TLR4,
was functionally active, we evaluated the binding of LPS.
The potential of Th1 inducers, like LPS and other
microbial exposures, to prevent or to mitigate allergy
and asthma is supported by the ﬁndings that the
treatment with LPS reduces allergic responses in atopics
(24) and that higher house dust endotoxin levels corre-
lated with increased proportions of IFNc producing cells
in the peripheral blood of infants (25). In this context,
several epidemiologic studies reported the reduced pre-
valence of allergy and asthma in rural areas in compar-
ison with urban areas (26) as well as the ﬁndings that LPS
levels were inversely related to hay fever, atopic asthma
and atopic sensitization but not to nonatopic asthma in
school-age children (9). However, a recent study, evalu-
ating an adult population, has reported that LPS expo-
sure is detrimental for asthma (27). To reconcile this
paradox, it is possible to argue that the timing of the LPS
exposure, the concentrations of LPS and the presence of
atopy determine the beneﬁcial or the detrimental eﬀects
of endotoxin (7, 9). As regards, it has been demonstrated
that LPS inhibits nasal allergic inﬂammation, by skewing
local immune responses from Th2 to Th1 and by
upregulating production of IL-10. All these beneﬁcial
eﬀects are mediated by TLR4 and are present in atopic
children but not in adults (24). In the present study, we
demonstrate for the ﬁrst time that the exposure to the 1–
55 hypoallergenic Par j 2 fragments increased, diﬀerently
to the native allergen, the LPS binding of PBMC from
allergic children with asthma. These ﬁndings allowed to
identify new advantages to use these compounds for the
therapy of allergic disorders in children. Moreover, innate
immune cells when stimulated by LPS via the activation
of recognition receptors for LPS (i.e. TLR4–CD14
complex) trigger nitric oxide synthase activity (28) and
induce a Th1-type T-lymphocyte response (with the
preferential production of IFNc) that promotes IgG
production generating a positive feedback loop that, in
turn, limits the Th2-mediated responses and the IgE
production (22). Here, we provide data concerning the
ability of the 1–55 fragment to increase the release of
IFNc by stimulated PBMC. Predominant Th1 responses,
via the production of IFNc, might divert the development
of atopy as well as of pathologic remodeling processes in
asthma. As regards, it has been demonstrated that IFNc
has the potential to provide a milieu for airway repair
without ﬁbrosis (26). While Th2 cytokines (IL-4 and IL-
13) stimulate ﬁbroblasts to proliferate and to produce
collagen in vitro (29), IFNc counteracts the collagen
synthesis (30), and antagonizes transforming growth
factor-b activities (31).
Furthermore, we pointed out that between the two
tested variants of Par j 2, only the 1–55 fragment has
the potential to divert the immune system of Par j 2
allergic children toward a more balanced equilibrium
between Th2 and Th1 responses. It is possible to
speculate that the epitopes of the 1–55 fragment are
preferentially recognized by professional APCs which,
in turn, upregulate the expression of innate immunity
receptors and increase the LPS binding and IFNc
release. All these intrinsic properties of this fragment
may be clinically relevant to improve the safe and the
success of SIT and to re-orientate, in atopics, the
immune system toward a physiologic balance between
Th1 and Th2 responses.
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